Oral News and Research

RSS

Results from Bionovo's study on BN107 published

Bionovo, Inc. announced today the publication of results from its study on the anti-tumor mechanism of BN107. The results of the study, published in the International Journal of Cancer, describe the potential molecular mechanisms mediating the selective pro-apoptotic (cell death) effect induced by BN107 on estrogen receptor negative (ER-) breast cancer cells.

29 Dec 2009

American Diabetes Association recommends A1C test for diagnosing diabetes and identifying pre-diabetes

The American Diabetes Association's new Clinical Practice Recommendations being published as a supplement to the January issue of Diabetes Care call for the addition of the A1C test as a means of diagnosing diabetes and identifying pre-diabetes. The test has been recommended for years as a measure of how well people are doing to keep their blood glucose levels under control.

29 Dec 2009

Children's Health Fund lauds Reid over release of the final Senate health care legislation

Irwin Redlener, MD, President and Co-founder of the Children's Health Fund, a national organization that advocates for and develops primary care programs for disadvantaged and medically underserved children, today released the following statement on release of the final Senate health care legislation by Majority Leader Harry Reid: "First and foremost, we applaud the Senate Majority Leader Harry Reid on producing this historic health reform bill which will provide millions of currently uninsured children access to comprehensive health insurance coverage.

24 Dec 2009

Salix Pharmaceuticals sued over alleged kidney damage due to OsmoPrep

Suits were commenced Dec. 23, 2009 in North Carolina for four users who allege kidney damage due to the use of OsmoPrep, a prescription drug used to cleanse the intestines in preparation for a colonoscopy. (Holshouser et al v. Salix Pharmaceuticals, Ltd. and Salix Pharmaceuticals. Inc.)

24 Dec 2009

Researchers unveil complete genetic make-up of cavity-causing bacterium

Researchers have uncovered the complete genetic make-up of the cavity-causing bacterium Bifidobacterium dentium Bd1, revealing the genetic adaptations that allow this microorganism to live and cause decay in the human oral cavity.

24 Dec 2009

AstraZeneca signs definitive agreement to acquire Novexel

Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial drug resistance, announces today that its shareholders have signed a definitive agreement whereby Novexel shall be acquired by AstraZeneca for a total cash consideration of up to $505 million, including contingent payments and the net cash position of the company at closing.

24 Dec 2009

Ligand Pharmaceuticals acquires Neurogen

Ligand Pharmaceuticals Incorporated announced today that it has completed the acquisition of Neurogen Corporation, following approval of the transaction by Neurogen stockholders earlier today. As a result, Ligand gains a fully funded partnership with Merck & Co., additional pipeline assets, drug discovery resources and additional cash balances.

23 Dec 2009

National MS Society calls for grant applications to examine the impact of CCSVI hypothesis

2009 saw exciting research progress, unprecedented opportunities on the horizon, and more scientists than ever working on resolving important questions. Despite the year's economic and financial challenges, the National Multiple Sclerosis Society continues to propel research forward to end MS. In 2009 the Society provided over $33.5 million to support 345 new and ongoing projects in its research portfolio, plus $1.5 million for Fast Forward, the Society's drug development subsidiary which continues to attract new funding streams.

23 Dec 2009

US Phase 2 clinical trial of RVX-208 commenced by Resverlogix

Resverlogix Corp. ("Resverlogix" or the "Company") announced today that it has begun dosing patients in its US Phase 2 clinical trial lead by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with stable coronary artery disease (CAD).

23 Dec 2009

Endocannabinoid modulation of sweet taste receptors may help control feeding behavior

Sweet taste responses were enhanced by endocannabinoids in every case. The effect was specific for sweet taste, as endocannibinoids had no effect on responses to sour, salty, bitter or umami taste stimuli.

22 Dec 2009

Emisphere's oral salmon calcitonin product addresses persistent musculoskeletal pain

Emisphere Technologies, Inc. today announced a meta-analysis published in the December 2009 edition of Rheumatology Reports examining independent evidence of the analgesic action of the hormone calcitonin. This publication restates the potential of calcitonin in filling a significant unmet need for alternative treatments for persistent musculoskeletal pain.

22 Dec 2009

DMC launches Dental Optimizer, a free online application connected to Microsoft HealthVault

While politicians and pundits continue to arm wrestle the minutiae of health reform, more and more Americans are stepping up to take charge of their own health.

22 Dec 2009

Proline repeats make teeth strong and resilient

A simple amino acid that is repeated in the center of proteins found in tooth enamel makes teeth stronger and more resilient, according to new research at the University of Illinois at Chicago.

22 Dec 2009

Effectiveness of VSEL stem cells in regenerative medicine demonstrated at the ASH meeting

NeoStem, Inc. (NYSE Amex: NBS), which is a leading provider of pre-disease adult stem cell collection, processing and long-term storage services, and holds the exclusive, worldwide license to VSEL(TM) technology that uses very small embryonic-like stem cells isolated from peripheral blood, announced today that five posters and two oral presentations at the prestigious American Society of Hematology (ASH) Annual Meeting in New Orleans in early December demonstrated the basic cellular mechanisms of very small embryonic-like stem cells.

21 Dec 2009

CPEX Pharmaceuticals completes enrollment in Nasulin Phase 2a clinical trial

CPEX Pharmaceuticals, Inc. today announced that the ongoing Phase 2a clinical trial of Nasulin™, the Company’s intranasal insulin candidate, has now completed enrollment. The study was initiated in February of this year and randomized 94 subjects. Results are expected at the end of the first quarter or beginning of the second quarter of 2010.

21 Dec 2009

Organogenesis files a PMA with the FDA for its CelTx living cell-based technology

Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.

21 Dec 2009

Eli Lilly, Incyte announce collaboration for development and commercialization of INCB28050 oral inhibitor

Eli Lilly and Company and Incyte Corporation announced today that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Incyte's oral JAK1/JAK2 inhibitor, INCB28050, and certain follow on compounds, for inflammatory and autoimmune diseases. The lead compound, INCB28050, is currently being studied in a six-month dose-ranging Phase II trial for rheumatoid arthritis.

21 Dec 2009

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

Intra-Cellular Therapies, Inc. (ITI) announced at a recent conference on neuropsychiatric diseases the results from a recently completed Phase I clinical study demonstrating ITI-007, the Company's lead antipsychotic drug, interacts with important targets in the living human brain. These key targets are critical to drug action in many neuropsychiatric and related disorders.

21 Dec 2009

Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated a Phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), for the prevention of acute radiation enteritis.

21 Dec 2009

Bran flakes with raisins and added sugar promote plaque acid

Elevated dental plaque acid is a risk factor that contributes to cavities in children. But eating bran flakes with raisins containing no added sugar does not promote more acid in dental plaque than bran flakes alone, according to new research at the University of Illinois at Chicago.

19 Dec 2009

Oral News and Research

Results from Bionovo's study on BN107 published

American Diabetes Association recommends A1C test for diagnosing diabetes and identifying pre-diabetes

Children's Health Fund lauds Reid over release of the final Senate health care legislation

Salix Pharmaceuticals sued over alleged kidney damage due to OsmoPrep

Researchers unveil complete genetic make-up of cavity-causing bacterium

AstraZeneca signs definitive agreement to acquire Novexel

Ligand Pharmaceuticals acquires Neurogen

National MS Society calls for grant applications to examine the impact of CCSVI hypothesis

US Phase 2 clinical trial of RVX-208 commenced by Resverlogix

Endocannabinoid modulation of sweet taste receptors may help control feeding behavior

Emisphere's oral salmon calcitonin product addresses persistent musculoskeletal pain

DMC launches Dental Optimizer, a free online application connected to Microsoft HealthVault

Proline repeats make teeth strong and resilient

Effectiveness of VSEL stem cells in regenerative medicine demonstrated at the ASH meeting

CPEX Pharmaceuticals completes enrollment in Nasulin Phase 2a clinical trial

Organogenesis files a PMA with the FDA for its CelTx living cell-based technology

Eli Lilly, Incyte announce collaboration for development and commercialization of INCB28050 oral inhibitor

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention

Bran flakes with raisins and added sugar promote plaque acid

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News